Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC).

Sherwood JL, Corcoran C, Brown H, Sharpe AD, Musilova M, Kohlmann A.

PLoS One. 2016 Feb 26;11(2):e0150197. doi: 10.1371/journal.pone.0150197. eCollection 2016.

2.

Optimization of circulating cell-free DNA recovery for KRAS mutation and HPV detection in plasma.

Mazurek AM, Fiszer-Kierzkowska A, Rutkowski T, Składowski K, Pierzyna M, Scieglińska D, Woźniak G, Głowacki G, Kawczyński R, Małusecka E.

Cancer Biomark. 2013;13(5):385-94. doi: 10.3233/CBM-130371.

PMID:
24440979
3.

Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing.

Medina Diaz I, Nocon A, Mehnert DH, Fredebohm J, Diehl F, Holtrup F.

PLoS One. 2016 Nov 10;11(11):e0166354. doi: 10.1371/journal.pone.0166354. eCollection 2016.

4.

Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies.

Freidin MB, Freydina DV, Leung M, Montero Fernandez A, Nicholson AG, Lim E.

Clin Chem. 2015 Oct;61(10):1299-304. doi: 10.1373/clinchem.2015.242453. Epub 2015 Aug 13.

5.

Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma.

Guibert N, Pradines A, Farella M, Casanova A, Gouin S, Keller L, Favre G, Mazieres J.

Lung Cancer. 2016 Oct;100:1-4. doi: 10.1016/j.lungcan.2016.07.021. Epub 2016 Jul 22.

PMID:
27597273
6.

Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer.

Normanno N, Denis MG, Thress KS, Ratcliffe M, Reck M.

Oncotarget. 2017 Feb 14;8(7):12501-12516. doi: 10.18632/oncotarget.13915. Review.

7.

The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA.

Parpart-Li S, Bartlett B, Popoli M, Adleff V, Tucker L, Steinberg R, Georgiadis A, Phallen J, Brahmer J, Azad N, Browner I, Laheru D, Velculescu VE, Sausen M, Diaz LA Jr.

Clin Cancer Res. 2017 May 15;23(10):2471-2477. doi: 10.1158/1078-0432.CCR-16-1691. Epub 2016 Nov 8.

8.

EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.

Thress KS, Brant R, Carr TH, Dearden S, Jenkins S, Brown H, Hammett T, Cantarini M, Barrett JC.

Lung Cancer. 2015 Dec;90(3):509-15. doi: 10.1016/j.lungcan.2015.10.004. Epub 2015 Oct 9.

9.

Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer.

Ohira T, Sakai K, Matsubayashi J, Kajiwara N, Kakihana M, Hagiwara M, Hibi M, Yoshida K, Maeda J, Ohtani K, Nagao T, Nishio K, Ikeda N.

Cancer Sci. 2016 Nov;107(11):1660-1666. doi: 10.1111/cas.13068.

10.

Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC.

Dowler Nygaard A, Spindler KL, Pallisgaard N, Andersen RF, Jakobsen A.

Oncol Rep. 2014 Feb;31(2):969-74. doi: 10.3892/or.2013.2906. Epub 2013 Dec 6.

PMID:
24316734
11.

Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing.

Chen KZ, Lou F, Yang F, Zhang JB, Ye H, Chen W, Guan T, Zhao MY, Su XX, Shi R, Jones L, Huang XF, Chen SY, Wang J.

Sci Rep. 2016 Aug 24;6:31985. doi: 10.1038/srep31985.

12.

Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).

Lim EH, Zhang SL, Li JL, Yap WS, Howe TC, Tan BP, Lee YS, Wong D, Khoo KL, Seto KY, Tan L, Agasthian T, Koong HN, Tam J, Tan C, Caleb M, Chang A, Ng A, Tan P.

J Thorac Oncol. 2009 Jan;4(1):12-21. doi: 10.1097/JTO.0b013e3181913e28.

13.

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.

Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem E.

Lancet Oncol. 2015 Aug;16(8):937-48. doi: 10.1016/S1470-2045(15)00138-2. Epub 2015 Jul 13.

PMID:
26184520
14.

Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes.

Kang Q, Henry NL, Paoletti C, Jiang H, Vats P, Chinnaiyan AM, Hayes DF, Merajver SD, Rae JM, Tewari M.

Clin Biochem. 2016 Dec;49(18):1354-1360. doi: 10.1016/j.clinbiochem.2016.03.012. Epub 2016 Apr 27.

PMID:
27129799
15.

A Comparison of Cell-Free DNA Isolation Kits: Isolation and Quantification of Cell-Free DNA in Plasma.

Sorber L, Zwaenepoel K, Deschoolmeester V, Roeyen G, Lardon F, Rolfo C, Pauwels P.

J Mol Diagn. 2017 Jan;19(1):162-168. doi: 10.1016/j.jmoldx.2016.09.009. Epub 2016 Nov 17.

PMID:
27865784
16.

Application of circulating tumor DNA in prospective clinical oncology trials - standardization of preanalytical conditions.

van Dessel LF, Beije N, Helmijr JC, Vitale SR, Kraan J, Look MP, de Wit R, Sleijfer S, Jansen MP, Martens JW, Lolkema MP.

Mol Oncol. 2017 Mar;11(3):295-304. doi: 10.1002/1878-0261.12037. Epub 2017 Feb 22.

17.

Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.

Spindler KL, Pallisgaard N, Appelt AL, Andersen RF, Schou JV, Nielsen D, Pfeiffer P, Yilmaz M, Johansen JS, Hoegdall EV, Jakobsen A, Jensen BV.

Eur J Cancer. 2015 Nov;51(17):2678-85. doi: 10.1016/j.ejca.2015.06.118. Epub 2015 Oct 24.

PMID:
26508156
18.

[What future for circulating tumor DNA? Current data and prospects in colorectal, non-small cell lung and pancreatic cancers].

Pietrasz D, Pécuchet N, Fabre E, Blons H, Chevalier L, Taly V, Laurent-Puig P, Bachet JB.

Bull Cancer. 2016 Jan;103(1):55-65. doi: 10.1016/j.bulcan.2015.10.017. Epub 2016 Jan 11. Review. French.

PMID:
26790710
19.

A modified extraction method of circulating free DNA for epidermal growth factor receptor mutation analysis.

Yuan H, Zhu ZZ, Lu Y, Liu F, Zhang W, Huang G, Zhu G, Jiang B.

Yonsei Med J. 2012 Jan;53(1):132-7. doi: 10.3349/ymj.2012.53.1.132.

20.

[Clinical implications of the concentration and EGFR/KRAS mutations of plasma cell free DNA of patients with lung cancer and esophageal cancer].

Zhang R, Li Y, Chen Y, Liu X, Wang Z, Sun H, Zheng Y, Ding Z, Lan L, Li M, Qin J, Chen X.

Zhonghua Yi Xue Za Zhi. 2015 Dec 15;95(47):3839-42. Chinese.

PMID:
27337801

Supplemental Content

Support Center